Suraksha Diagnostic DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025


0.72×	0.70×	0.75×
0.83×	0.83×	0.90×
18.1%	17.4%	18.2%
0.79×	0.79×	0.76×
1.84×	1.84×	1.59×
15.7%	14.7%	14.8%
14.1%	14.1%	15.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SURAKSHA₹319.55

Suraksha Diagnostic Limited

· Pharma & Health

₹ CrorePeersKRSNAA HEALTHX NEPHROPLUS 3BBLACKBIOMcap ₹1,664 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.70	0.72
Interest Burden (Pretax/EBIT) ×	0.90	0.83	0.83
EBIT Margin %	18.23	17.38	18.08
Asset Turnover ×	0.76	0.79	0.79
Financial Leverage (Assets/Equity) ×	1.59	1.84	1.84
ROE (5-step product, year-end total equity) %	14.82	14.71	15.67
ROE (owners' profit / average owners' equity) %	15.06	14.11	14.11

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.